1. Academic Validation
  2. The activity of the aryl hydrocarbon receptor in T cells tunes the gut microenvironment to sustain autoimmunity and neuroinflammation

The activity of the aryl hydrocarbon receptor in T cells tunes the gut microenvironment to sustain autoimmunity and neuroinflammation

  • PLoS Biol. 2023 Feb 14;21(2):e3002000. doi: 10.1371/journal.pbio.3002000.
Andrea R Merchak 1 2 3 Hannah J Cahill 1 Lucille C Brown 1 Ryan M Brown 1 2 3 Courtney Rivet-Noor 1 2 3 Rebecca M Beiter 1 2 3 Erica R Slogar 1 Deniz G Olgun 1 Alban Gaultier 1 3
Affiliations

Affiliations

  • 1 Department of Neuroscience, University of Virginia, Charlottesville, Virginia, United States of America.
  • 2 Neuroscience Graduate Program, University of Virginia, Charlottesville Virginia, United States of America.
  • 3 Center for Brain Immunology and Glia, University of Virginia, Charlottesville, Virginia, United States of America.
Abstract

Multiple sclerosis (MS) is a T cell-driven autoimmune disease that attacks the myelin of the central nervous system (CNS) and currently has no cure. MS etiology is linked to both the gut flora and external environmental factors but this connection is not well understood. One immune system regulator responsive to nonpathogenic external stimuli is the Aryl Hydrocarbon Receptor (AHR). The AHR, which binds diverse molecules present in the environment in barrier tissues, is a therapeutic target for MS. However, AHR's precise function in T lymphocytes, the orchestrators of MS, has not been described. Here, we show that in a mouse model of MS, T cell-specific Ahr knockout leads to recovery driven by a decrease in T cell fitness. At the mechanistic level, we demonstrate that the absence of AHR changes the gut microenvironment composition to generate metabolites that impact T cell viability, such as bile salts and short chain fatty acids. Our study demonstrates a newly emerging role for AHR in mediating the interdependence between T lymphocytes and the microbiota, while simultaneously identifying new potential molecular targets for the treatment of MS and other autoimmune diseases.

Figures
Products